1246 related articles for article (PubMed ID: 21605038)
21. Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.
Koss DJ; Jones G; Cranston A; Gardner H; Kanaan NM; Platt B
Acta Neuropathol; 2016 Dec; 132(6):875-895. PubMed ID: 27770234
[TBL] [Abstract][Full Text] [Related]
22. Glial contributions to neurodegeneration in tauopathies.
Leyns CEG; Holtzman DM
Mol Neurodegener; 2017 Jun; 12(1):50. PubMed ID: 28662669
[TBL] [Abstract][Full Text] [Related]
23. Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.
Vergara C; Ordóñez-Gutiérrez L; Wandosell F; Ferrer I; del Río JA; Gavín R
Mol Neurobiol; 2015; 51(3):1206-20. PubMed ID: 24965601
[TBL] [Abstract][Full Text] [Related]
24. Tau Proteins and Tauopathies in Alzheimer's Disease.
Chong FP; Ng KY; Koh RY; Chye SM
Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
[TBL] [Abstract][Full Text] [Related]
25. A NH2 tau fragment targets neuronal mitochondria at AD synapses: possible implications for neurodegeneration.
Amadoro G; Corsetti V; Stringaro A; Colone M; D'Aguanno S; Meli G; Ciotti M; Sancesario G; Cattaneo A; Bussani R; Mercanti D; Calissano P
J Alzheimers Dis; 2010; 21(2):445-70. PubMed ID: 20571215
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
27. Prospect of therapeutic approaches to tauopathies.
Roder HM
J Mol Neurosci; 2003 Apr; 20(2):195-202. PubMed ID: 12794313
[TBL] [Abstract][Full Text] [Related]
28. Tau aggregation is a therapeutic target for Alzheimer's disease.
Takashima A
Curr Alzheimer Res; 2010 Dec; 7(8):665-9. PubMed ID: 20678070
[TBL] [Abstract][Full Text] [Related]
29. Tau therapeutic strategies for the treatment of Alzheimer's disease.
Churcher I
Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
[TBL] [Abstract][Full Text] [Related]
30. Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer's disease and other tauopathies.
Xia Y; Prokop S; Gorion KM; Kim JD; Sorrentino ZA; Bell BM; Manaois AN; Chakrabarty P; Davies P; Giasson BI
Acta Neuropathol Commun; 2020 Jun; 8(1):88. PubMed ID: 32571418
[TBL] [Abstract][Full Text] [Related]
31. Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus.
Zhang ZX; Zhao RP; Wang DS; Li YB
Neurochem Res; 2016 Nov; 41(11):3074-3082. PubMed ID: 27518086
[TBL] [Abstract][Full Text] [Related]
32. Modulation of Tau Pathology in Alzheimer's Disease by Dietary Bioactive Compounds.
Shi H; Zhao Y
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255905
[TBL] [Abstract][Full Text] [Related]
33. Identification of key amino acids responsible for the distinct aggregation properties of microtubule-associated protein 2 and tau.
Xie C; Soeda Y; Shinzaki Y; In Y; Tomoo K; Ihara Y; Miyasaka T
J Neurochem; 2015 Oct; 135(1):19-26. PubMed ID: 26134402
[TBL] [Abstract][Full Text] [Related]
34. Current strategies for the treatment of Alzheimer's disease and other tauopathies.
Dickey CA; Petrucelli L
Expert Opin Ther Targets; 2006 Oct; 10(5):665-76. PubMed ID: 16981824
[TBL] [Abstract][Full Text] [Related]
35. Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains.
Nagamine S; Yamazaki T; Makioka K; Fujita Y; Ikeda M; Takatama M; Okamoto K; Yokoo H; Ikeda Y
Neuropathology; 2016 Aug; 36(4):333-45. PubMed ID: 26685795
[TBL] [Abstract][Full Text] [Related]
36. Tauopathies and tau oligomers.
Takashima A
J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
[TBL] [Abstract][Full Text] [Related]
37. Sources of extracellular tau and its signaling.
Avila J; Simón D; Díaz-Hernández M; Pintor J; Hernández F
J Alzheimers Dis; 2014; 40 Suppl 1():S7-S15. PubMed ID: 24531154
[TBL] [Abstract][Full Text] [Related]
38. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease.
Kayed R
Hum Vaccin; 2010 Nov; 6(11):931-5. PubMed ID: 20980799
[TBL] [Abstract][Full Text] [Related]
39. Rho-kinase ROCK inhibitors reduce oligomeric tau protein.
Hamano T; Shirafuji N; Yen SH; Yoshida H; Kanaan NM; Hayashi K; Ikawa M; Yamamura O; Fujita Y; Kuriyama M; Nakamoto Y
Neurobiol Aging; 2020 May; 89():41-54. PubMed ID: 31982202
[TBL] [Abstract][Full Text] [Related]
40. Altered Proteostasis in Neurodegenerative Tauopathies.
Papanikolopoulou K; Skoulakis EMC
Adv Exp Med Biol; 2020; 1233():177-194. PubMed ID: 32274757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
